News
For years, there was no stopping Novo Nordisk, the Danish drugmaker behind Ozempic. Its diabetes drug became a cultural ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...
Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Most dividend yields ...
Flush with Trump connections, Ballard Partners is D.C.’s new lobbying powerhouse — and its clients are reaping the benefits.
Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...
Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s sustained over time, a new study found.
Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short ...
The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results